Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
CTM-N2D
Phase 1 mab active
Quick answer
Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell for Colorectal Cancer is a Phase 1 program (mab) at CytoMed Therapeutics Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CytoMed Therapeutics Ltd
- Indication
- Colorectal Cancer
- Phase
- Phase 1
- Modality
- mab
- Status
- active